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Breast calciﬁcations, deﬁned as calcium deposits within breast tissue, can arise from a vast
number of aetiologies. Diffuse or scattered distribution is typically seen in benign entities.
Approximately 95% of all Ductal carcinoma-in-situ, which represents 25e30% of all re-
ported breast cancers are diagnosed because of mammographically detected micro-
calciﬁcations. In this investigation dedicated to breast calciﬁcations, we assessed at the
micrometer scale their chemical nature through last generation micro-Fourier transform
Infrared microspectroscopy and their structural characteristics through last generation
ﬁeld emission scanning electron microscopy. Several striking results have been obtained.
Heavily mineralized deposits seem to be the result of the agglomeration of micrometer
scale spherules and for the ﬁrst time, we show that micrometer scale spherules display
very different internal structure. Moreover, while Ca phosphate apatite and calcium oxa-
late dihydrate are the two chemical phases usually reported, we underline the presence of
a third chemical phase namely amorphous carbonated calcium phosphate. In the case of
duct carcinoma in situ (DCIS), the chemical composition as well as the carbonate level are
very inhomogeneous even inside micrometer scale breast calciﬁcations. Moreover, for
some samples related to DCIS, special features at the micrometer scale seem to be related
to this pathology because they were not found for the other pathologies.
© 2016 Published by Elsevier Masson SAS on behalf of Académie des sciences. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction female cases and 13% of the total). Breast cancer begins inBreast cancer is the most common cancer in Europe for
females [1], and the most common cancer overall, with
more than 464,000 new cases diagnosed in 2012 (29% ofd’anapathologie, 114
y.fr (A. Ben Lakhdar).
S on behalf of Académie de
).breast tissue, which is made up of glands for milk pro-
duction, called lobules, and the ducts that connect the
lobules to the nipple [2]. Some breast cancers are called in
situ because they are conﬁned within the ducts (ductal
carcinoma in situ or DCIS) or lobules (lobular carcinoma in
situ or LCIS) where they originated.
Mammographic mammary microcalciﬁcations are
routinely used for the early detection of breast cancer,s sciences. This is an open access article under the CC BY-NC-ND license
Table 1
Physiological and clinical data of the ﬁrst set of samples.
Sample Age (years) Disease
Sample A e 13H2480 65 Normal breast (duct)
Sample B e 13H2606 60 Fibroadenoma
Sample C e 13H2282 61 Galactophoric cyst
Sample D e 13H2427 57 Adenosis
Sample E 13H2281 62 Ductal carcinoma in situ (DCIS)
A. Ben Lakhdar et al. / C. R. Chimie 19 (2016) 1610e1624 1611however the mechanisms by which they form remain un-
clear [3] and for a long period of time they have been
considered as a passive phenomenon [4]. Recently, obser-
vations of cell phenotype led M. Scimeca et al. [5] to hy-
pothesize that under speciﬁc stimuli, mammary cells may
acquire some mesenchymal characteristics transforming
themselves into cells with an osteoblast-like phenotype
and are able to contribute to the production of breast
microcalciﬁcations. At this point, we may recall that the
presence of calciﬁcation may induce a signiﬁcant modiﬁ-
cation of the cellular metabolism, an inﬂammation or a
modiﬁcation of the phenotype [6,7].
Breast calciﬁcations deﬁned as calcium deposits within
breast tissue have thus been at the core of numerous
publications [8e25]. One of the difﬁculties comes from the
fact that breast calciﬁcations can arise from a vast number
of aetiologies. For example, diffuse or scattered distribution
is typically seen in benign entities. At the opposite,
approximately 95% of all DCIS, which represents 25e30% of
all reported breast cancers are diagnosed because of
mammographically detected microcalciﬁcations.
As underlined by T. Oyama et al. [26], two types of cal-
ciﬁcations have been described. Type I mcalciﬁcations
appear as colorless, birefringent crystals composed of
weddellite or calcium oxalate dihydrate (CaC2O4e2H2O).
They most often form in apocrine cysts and less commonly
in other benign conditions. Type II mcalciﬁcations, which
consist of apatite, occur in both benign and malignant
conditions [27,28]. Note that, calcium oxalate has three
different crystalline forms: calcium oxalate monohydrate
(whewellite e CaC2O4eH2O) [29e35], is the most stable
[36], Calcium oxalate dihydrate [37e40] and ﬁnally calcium
oxalate trihydrate (caoxitedCaC2O4e3H2O) which is rarely
observed under physiological conditions [41]. From a
chemical point of view, the fact that only calcium oxalate
dihydrate, a species which normally leads to calcium oxa-
late monohydrate, seems to indicate that a particular sta-
bilization process exists.
Regarding breast calciﬁcations made of carbonated
calcium phosphate apatite (CA), S.H. Poggi et al. [42] have
described through Scanning Electron Microscopy (SEM)
two morphologies, namely spherical entities and heavily
mineralized deposits. These authors have also pointed out
local composition variations. Finally, R. Baker et al. [43]
have noticed that the carbonate content of breast CA
mcalciﬁcations was shown to be signiﬁcantly different be-
tween benign and malignant disease. The importance of
morphology and chemical nature has been underlined for
other kinds of pathological calciﬁcations such as kidney
[31,32,44,45] or prostatic [46,47] calciﬁcations.
Finally, let us note that the majority of micro-
calciﬁcations are concretions of varying size composed of
calcium phosphates largely in the form of Ca phosphate
apatite. In ductal carcinoma in situ, calciﬁcations are
formed by deposition of calcium on nuclear debris or in
secreted mucosubstances. The other type of micro-
calciﬁcations, calcium oxalate crystals, is seen in micro-
cysts, especially with apocrine epithelium. This
association suggests that apocrine epithelium is able to
synthetize or concentrate and secrete oxalic acid or cal-
cium oxalate.All these investigations demonstrate clearly that the
establishment of a signiﬁcant relationship between breast
mcalciﬁcations and their aetiology calls for a precise struc-
tural and chemical description of these biological entities
[48,49]. In this study, we have selected a set of breast bi-
opsies in which the presence of apatite calciﬁcations have
been already underlined through HES (Hema-
teineEosineSafran) staining procedures performed at the
hospital. In order to describe their structural characteristics
at the micrometer scale, observations with a Field Emission
SEM (FE-SEM) have been done. On the very same samples,
their chemical identiﬁcation at the micrometer scale has
been made through mFourier Transform Infra-Red (mFT-IR)
spectroscopy [50e56]. Such precise description of these
pathological calciﬁcations may lead to a better under-
standing of their pathogenesis.2. Experimental
A set of ﬁve breast biopsies (Samples A to E) was inves-
tigated in order to shed light on the complexity of the
structural and chemical characteristics of ectopic calciﬁca-
tions in breast tissues (Tables 1 and 2). The second set of
samples (Samples H to Q) is used to establish a possible
relationship between the pathology and the structural and
chemical parameters of breast calciﬁcations. In theﬁrst step,
we select benign calciﬁcations and one related to DCIS. The
biological samples came from Gustave Roussy Institute
(Villejuif, France). Fivemicrometer sections of biopsiesﬁxed
in formalin andparafﬁnembeddedweredeposited on low-e
microscope slides (MirrIR, Kevley Technologies, Tienta Sci-
ences, Indianapolis). Ethical approval was obtained by the
ethical committee of IGR for this study. Each sample was
only named by a study number, without indicating the
name of the patient or potential identiﬁcation data.
A Zeiss SUPRA55-VP SEM was used for observation of
microstructure. Thisﬁeld-effect “gun”microscope (FE-SEM)
operates at 0.5e30 kV. High-resolution observations were
obtained by 2 secondary electron detectors: an in-lens SE
detector and an EverharteThornley SE detector. Tomaintain
the integrity of the samples, measurements were taken at
low voltage (between 0.5 and 2 kV) without the usual
deposits of carbon at the surface of the sample [57,58].
IR microspectroscopy was performed on an IN10MX
microscope (Thermo Scientiﬁc) for recording large maps.
All spectra were collected in ultrafast mode using a
50 mm  50 mm aperture. The spectra were collected in the
4000e700 cm1 mid-IR range at a resolution of 8 cm1
with one spectrum per pixel. Data analysis of IR spectra and
Table 2
Physiological and clinical data of the second set of samples.
Sample Age (years) Disease
Sample F e 13H3279 60 DCIS
Sample G e 13H6529 55 DCIS
Sample H e 13H2851 66 DCIS
Sample I e 13H1096 70 DCIS
Sample J e 13H8746 66 DCIS
Sample K e 14H2554 37 Benign
Sample L e 14H4540 50 Benign
Sample M e 13H4111 63 Benign
A. Ben Lakhdar et al. / C. R. Chimie 19 (2016) 1610e16241612chemical images was performed using OMNIC software
(Thermo Scientiﬁc).3. Results and discussion
From a crystallographic point of view, the apatite pro-
totype structure was ﬁrst determined by Naray-Szabo [59]
and are conventionally regarded as conforming to the
A5(BO4)3X general chemical formula (P63/m symmetry)Fig. 1. FE-SEM observations of sample A (13H2480 e Normal breast) at low (a) and
magniﬁcations can be visualized.[60]. At this point, we would like to recall that hydroxy-
apatite can be described as a hexagonal stacking of (PO4)3
groups with two kinds of tunnels parallel to the c axis. The
ﬁrst one coincides with the ternary axis of the structure and
is occupied by Ca2þ, noted as Ca(I) ions. The second one is
linked by oxygen and other calcium ions, noted Ca(II), and
is occupied by OH ions. Ca(I) and Ca(II) are present in a 2/3
ratio [61e63].
Regarding biological samples, CA calciﬁcations display
generally a hierarchical structure at different scales
[64e66]. Biological apatites result from the agglomeration
of nanocrystals [67,68]. Their nanometer size with an
anisotropy along the c axis [69] is combined with a high Ca
and OH deﬁciency [70,71]. CO32 carbonate groups [72]
and trace elements [73] such as Mg2þ [74e76], Zn2þ
[77e83] or Sr2þ [84e87] can be found inside or at their
surface while an amorphous part (ACCP for amorphous
carbonated calcium phosphate) [88] is located at the sur-
face of the nanometer size crystal. CO3
2 carbonate anions
substitute partially phosphate ions (PO4
3) (B-type) or
hydroxide ions (OH) (A-type). For the position of CO32
ions (A-type) six possibilities around the c axis are in facthigh (b,c,d, and e) magniﬁcations. Different mineralized deposits at various
A. Ben Lakhdar et al. / C. R. Chimie 19 (2016) 1610e1624 1613possible for a same chemical composition [89]. Interest-
ingly, a supplementary species of carbonate, i.e. a labile
carbonate, has been underlined [90]. Thus biological apa-
tites can be represented by the following formulae:
Ca10xþu,xuðPO4Þ6xðCO3ÞxðOHÞ2xþ2u
with, corresponding to vacancy; x  2 and u  x=2:
At the micrometer scale, different morphologies can be
observed for CA calciﬁcations. In a recent paper focused on
kidney stones [91], CA particles appeared as spherules of
4.5 ± 3.0 mm in diameter and were signiﬁcantly larger in
females than in males. Note that spherical entities have
been also identiﬁed in human cardiovascular tissue calci-
ﬁcation [92]. Also, the description of the surface of CA
particles may provide major clinical information regarding
the infection process involved in CA formation as shown for
kidney stones [93].
Investigations performed through vibrational spec-
troscopies, namely mFTIR and Raman spectroscopies, have
been also used for studying biological CA [47,94e99].
Raman experiments may also play a major role regarding
the guidance of stereotactic breast needle biopsies for
microcalciﬁcations [100]. I. Barman et al. [101] show the
potential of Raman spectroscopy to concomitantly detect
microcalciﬁcations and diagnose associated lesions. Such
an investigation provides real-time feedback to radiolo-
gists during such biopsy procedures, reducing non-
diagnostic and false-negative biopsies. Quite recently, it
was found from Raman spectroscopic analysis of CA
mcalciﬁcations that the carbonate content is greater in CAFig. 2. (a) FE-SEM observations of sample B (13H2606- Fibroadenoma) showing he
cation. (b) and (c) micrometer scale spherules corresponding to the black circle ofcalciﬁcations from benign than malignant breast tissue
[102]. Also, a signiﬁcant correlation was observed between
carbonate concentrations and carcinoma-in-situ sub-
grades [14]. Taking into account the small size of the
crystallites, Raman spectroscopy seems to be even more
effective than FTIR but this technique has several draw-
backs. Some patients present extremely low quantities of
ectopic calciﬁcation with fragile, organic, and micrometer-
sized crystals; we have already observed that chemical
characterization through Raman spectroscopy even at very
low power induces signiﬁcant alterations of their
morphology. Moreover, even in the case of ectopic calci-
ﬁcations made of whewellite microcrystals, Raman spec-
troscopy can induce signiﬁcant modiﬁcations. As a
preliminary conclusion, all these studies underline the
different structural parameters which have to be discussed
in the case of CA calciﬁcations [7].
The starting point of this study is given by FE-SEM ob-
servations performed on benign calciﬁcations (sample A-
13H2480). On Fig.1, a set of FE-SEM photographs at low and
high magniﬁcations has been gathered. As we can see,
normal breast calciﬁcations can be observed in detail.
In Fig. 2, we have considered the sample B (13H2606)
(which is related to ﬁbroadenoma). In that case, heavily
mineralized deposits (black arrows in Fig. 2a) as well as
micrometer scale spherules at different magniﬁcations
(inside the black circle in Fig. 2a and then in Fig. 2b and c at
higher magniﬁcations) are shown.
Such an observation is in line with previous measure-
ments performed by S.H. Poggi et al. [42] which have
already underlined the presence of two kinds of CAavily mineralized deposits and very small entities invisible at this magniﬁ-
Fig. 2a are visualized at higher magniﬁcations.
Fig. 3. (aeh) All these SEM observations (Sample B: 13H2606- Fibroadenoma; Sample C: 13H2282 Galactophoric cyst; Sample D: 13H2427dAdenosis) show that
some of the heavily mineralized deposits seem to be the result of the agglomeration of micrometer scale spherules.
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Fig. 4. Sample B (13H2606- Fibroadenoma). Different internal structures of CA sphericules. (a) Radial structure; (b) and (c) concentric layers; (d) radial structure.
Fig. 5. Sample E (13H2281 e Ductal carcinoma in situ) (a) Optical image
collected by the FTIR spectrometer. (b) Typical infrared spectrum: (1) n1 PeO
stretching vibration modes are measured at 960e962 cm1; (2) n3 PeO
stretching vibration modes are measured at 1035e1045 cm1; (3) Particular
attention has to be paid to the presence of a feature in the n3 absorption
band, which can be used as a ﬁngerprint for the presence of ACCP; (4 and 5)
absorption bands due to the presence of carbonate. (c) Spatial repartition of
Ca phosphate apatite in the breast biopsy. Red cross marks in Fig. 5a and c
correspond to the points of measurement.
Fig. 6. Sample C (13H2282- Galactophoric cyst) (a) Optical image collected
by the FTIR spectrometer. (b) Typical infrared spectrum. (c) Spatial reparti-
tion of Ca phosphate apatite in the breast biopsy as given by the absorption
bands at 1000 cm1. Red cross marks in Fig. 6a and c correspond to the
points of measurement.
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Fig. 7. Sample E (13H2281-Ductal carcinoma in situ): (a) and (b) SEM observations at two different magniﬁcations. Note the absence of spherical entities.
A. Ben Lakhdar et al. / C. R. Chimie 19 (2016) 1610e16241616deposits. More interestingly, another set of SEM observa-
tions establish a possible link between these two kinds of
CA deposits. As we can see in Fig. 3aeh, heavily mineralized
deposits seem to be the result of the agglomeration of
micrometer scale spherules. Such an structural evolution
from micrometer scale spherules to “large” deposits is
observed for very different pathologies including ﬁbroa-
denoma (sample B), galactophoric cyst (sample C) and
adenosis (sample D).
Thanks to the development of the FE-SEM technology, it
is possible now to get a more precise description of these
spherules. The following set of SEM observations which
have been collected on the same sample (sample B) dem-
onstrates clearly that spherical entities may display very
different internal structures (Fig. 4). Some of them are
homogeneous (Fig. 4a) while for others, concentric layers
are present at the surface of the spherules (Fig. 4b and c).
Finally, some spherules seem to exhibit a radial structure
(Fig. 4a and d).
In order to determine precisely the chemical nature of
these abnormal deposits, FTIR experiments have been
performed (Fig. 5 for the sample E, Fig. 6 for the sample C)
(13H2282- Galactophoric cyst). As we can see on Figs. 5 and
6, the last generation FTIR experimental device allows the
acquisition of the large map in a short time (around 30 mn)
with an excellent signal to noise ratio. Let’s just recall that
F.T.-I.R. spectroscopy probes the vibrational modes ofmolecules, providing a spectrum that is structure-speciﬁc
[103].
On Fig. 5 (Sample Ed13H2281d e Ductal carcinoma in
situ), data collected on the FTIR experimental set up and on
the FE-SEM device have been gathered. Fig. 5a shows the
optical map obtained while in Fig. 5c a typical infrared
spectrum is shown. The absorption bands measured at
960e962 cm1 and 1035e1045 cm1, correspond to n1 and
n3 PeO stretching vibrations, respectively, while the n4
OePeO bending mode corresponds to the doublet at
602e563 cm1 (Fig. 5b). The absorption band corre-
sponding to the n3 P-O 1030e1045 cm1 is clearly visible
while the doublets appearing at around 1410 cm1 and
1450 cm1 are due to the presence of carbonate inside the
CA crystals. The spatial repartition of CA (Fig. 5c) can be
estimated through a plot of the spatial repartition of the
intensity of the absorption peak located at 1030 cm1 (n3 P-
O). In the case of sample 1, this spatial repartition of CA
(Fig. 7c) given with FTIR data is in line with the SEM map
(Fig. 7d). Thus, we have for this breast biopsy a chemical
imaging as well as the morphology of the different CA
deposits.
Particular attention has to be paid to the presence of a
shoulder in the n3 absorption band, which can be used as a
ﬁngerprint for the presence of amorphous carbonated
calcium phosphate (ACCP). Its disappearance can be
considered as a marker for the presence of the ACCP
Fig. 8. Sample E (13H2281-Ductal carcinoma in situ) (a, b and c) location (given by the black star in the optical photograph) and FTIR spectra. The chemical
compositions as well as the carbonate level are very inhomogeneous: a) high proportion of PACC (black arrow) with a very high carbonation rate (red arrow); b)
high proportion of CA (black arrow) with a low carbonation rate (red arrow); c) spectrum of proteins with a low proportion of calcium phosphate (black arrow).
A. Ben Lakhdar et al. / C. R. Chimie 19 (2016) 1610e1624 1617compound, the n3 P-O peak of which being shifted at
around 1060 cm1. For the three samples (F, C and G) which
correspond respectively to ductal carcinoma in situ, gal-
actophoric cyst and sclerosis adenosis; FT-IR spectroscopy
underlines the presence of ACCP. To our knowledge, such a
chemical phase has never been identiﬁed in breast
calciﬁcation.
Finally, we would like to discuss the sample E
(13H2281-Ductal carcinoma in situ), for which we compare
different FTIR spectra collected for a same calciﬁcation. In
Fig. 7, SEM images of this structure which correspond to
duct carcinoma in situ at two different magniﬁcations are
shown (Fig. 7a and b). Note that it was not possible to
visualize spherical entities.
Then, for this feature, we collect FTIR spectra from the
core to the surface (Fig. 8aec). It is crystal clear that these
three spectra show clearly a signiﬁcant chemical hetero-
geneity inside the calciﬁcation. As underlined previously,
the presence of a shoulder in the n3 absorption band is
directly related to the presence of CA and its disappearance
to ACCP and a comparison between the two IR spectra
plotted in Fig. 8a and b is signiﬁcantly different. Moreover,
for this feature, a major variation of the CO3
2/PO4
3 ratio
is observed.
We would like to assess now the second set of samples
(Samples F to M) for which we try to establish a possiblerelationship between the physicochemical characteristics
of the calciﬁcations and the pathology. On these samples,
mFTIR experiments as well as FE-SEM observations at
different magniﬁcations have been performed. As an illus-
tration, experiments on sample F (Figs. 9 and 10) and
sample K (Figs. 11 and 12) are shown. For both samples,
mFTIR data indicate the presence of ACCP and CA.
At a ﬁrst sight, the complete set of observations per-
formed through FE-SEM seems to show that the two kinds
of calciﬁcations are quite similar (Fig. 13) One striking point
is related to the fact that for some samples (samples E,F and
G) related to DCIS, FE-SEM observations clearly show a
speciﬁc morphology at the micrometer scale (Fig. 14).
4. Conclusion
In this investigation, we have characterized ectopic
calciﬁcations in breast tissues using last generation exper-
imental devices i.e., FE-SEM and mFTIR spectrometer. Such
approach allows us to describe the morphology of these
mineral deposits and to identify precisely their chemical
nature. Several striking results have been obtained. While
the literature regarding ectopic calciﬁcations in breast tis-
sues [see for examples 8e25,104e108] shows that only two
chemical phases have been identiﬁed, through a careful
analysis of mFTIR spectroscopy, our study demonstrates
Fig. 9. Sample F e 13H3279 e DCIS: (a) Optical image collected by the FTIR spectrometer. (b) Spatial repartition of Ca phosphate apatite in the breast biopsy as
given by the absorption bands at 1000 cm1. (c) infrared absorption spectrum collected for the deposit a. (d) and (e) two infrared absorption spectra collected for
the deposit b showing various mixing of ACCP and CA.
Fig. 10. Sample F e 13H3279 eDCIS: (a) and (b) SEM observations at high magniﬁcation for the deposits a and b.
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Fig. 11. Sample K e 14H2554- benign: (a) Optical image collected by the FTIR spectrometer. (b) Spatial repartition of Ca phosphate apatite in the breast biopsy as
given by the absorption bands at 1000 cm1 (c) and (d) Infrared absorption spectra collected for the deposits a and b.
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Fig. 12. Sample K e 14H2554- benign: (a) optical map, FE-SEM observations at low (b) and high (c and d) magniﬁcations.
A. Ben Lakhdar et al. / C. R. Chimie 19 (2016) 1610e16241620
Fig. 13. SEM observations collected for different samples. Samples K and L are related to benign calciﬁcations while samples G,H and I are related to DCIS.
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Fig. 14. SEM observations collected for breast calciﬁcations (samples E,F and G) related to DCIS.
A. Ben Lakhdar et al. / C. R. Chimie 19 (2016) 1610e16241622clearly the presence of a third phase, namely ACCP (Fig. 8,
sample E). In the case of duct carcinoma in situ, this
chemical phasewas present at the center of the duct. At our
best knowledge, it is the ﬁrst time that this chemical phase
has been reported in ectopic calciﬁcations. Through mFTIR
spectroscopy, we underline a very inhomogeneous distri-
bution of the chemical phases as well as the carbonate
levels in the pathological calciﬁcations. It is thus very
difﬁcult to relate the carbonation rate of CA to the pathol-
ogy as previously suggested. Finally, SEM observations
underline a diversity in the internal structure of spherule
entities. For some samples related to DCIS, special features
at the micrometer scale seem to be related to this pathol-
ogy because they were not found for the other pathologies.
In order to establish a relationship between the physico-
chemical characteristics of the calciﬁcations and pathology,
a double blind trial has to be performed.
Moreover, as underlined in previous publications, we
can add data coming from other techniques. In the case of
ectopic calciﬁcations made of apatite, the presence of trace
elements such as Zn which can play a major role in the
pathogenesis, has to be assessed through X-ray ﬂuores-
cence [109e120] and one technique speciﬁc to synchro-
tron radiation, namely X-ray absorption spectroscopy
(XAS) [85,86,121e126]. For example, it is possible to un-
derline the inﬂammation process through the content of
Zn, an information which can be very important for a
clinician [113,114]. Through XAS, it is also possible to
assess the localisation of trace elements versus the calci-
ﬁcation [86].
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